Last $19.56 USD
Change Today +0.14 / 0.72%
Volume 34.3K
LMNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:52 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Open
$19.50
Previous Close
$19.42
Day High
$19.72
Day Low
$19.44
52 Week High
10/1/13 - $20.52
52 Week Low
04/28/14 - $15.74
Market Cap
839.9M
Average Volume 10 Days
142.3K
EPS TTM
$0.42
Shares Outstanding
42.8M
EX-Date
--
P/E TM
47.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The company operates in two segments: Technology and Strategic Partnerships (TSP); and Assays and Related Products (ARP). The TSP segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a versatile multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The ARP segment develops and sells assays on xMAP, xTAG, and MultiCode technology for use on its installed base of systems. It provides various assay products that consist of a combination of chemical and biological reagents; and company’s proprietary bead technology used to perform diagnostic and research assays on samples. This segment’s products are focused on the human genetics, personalized medicine, and infectious disease segments of the molecular diagnostic testing market. Luminex Corporation serves pharmaceutical companies, clinical laboratories, and research and medical institutions in the United States, Europe, Asia, Canada, Australia, and internationally. The company has collaboration with Merck & Co. Inc. to develop a companion diagnostic device. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

731 Employees
Last Reported Date: 02/26/14
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $700.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $320.9K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $319.2K
Senior Vice President of Research & Developme...
Total Annual Compensation: $345.6K
Compensation as of Fiscal Year 2013.

luminex corp (LMNX) Key Developments

Luminex Corporation Receives FDA Clearance to Add New Clinical Targets and Additional Sample Type for Use With xTAG Gastrointestinal Pathogen Panel

Luminex Corporation announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel. The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. In addition, FDA has now cleared xTAG GPP for use with specimens in Cary-Blair medium, a common transport medium for collection and preservation of microbiological specimens. As the first multiplexed U.S. IVD cleared test for infectious gastroenteritis, xTAG GPP simultaneously detects 14 common viral, bacterial, and parasitic causative pathogens from a single patient sample. By testing for greater than 90% of the causative pathogens of infectious gastroenteritis in a single test, clinicians can more quickly identify and treat the causative agent. Additionally co-infections can be more easily identified. Simultaneous molecular testing on a single sample within a single shift also provides significant benefits to laboratories in terms of workflow and resource utilization. The ability to scale throughput by processing 96-well plates allows laboratories to easily tailor their sample processing to physician demand.

Luminex Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:10 AM

Luminex Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:10 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Patrick J. Balthrop, Chief Executive Officer, President, Director, Member of Executive Committee and Member of Strategy & Development Committee.

Luminex Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Revenue Guidance for the Year 2014

Luminex Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $55,632,000 against $54,287,000 for the same period in the last year. Income from operations was $4,771,000 against $5,041,000 the same period in the last year. Income before income taxes was $4,770,000 against $5,117,000 for the same period in the last year. Net income was $4,725,000 or $0.11 per diluted share against $3,695,000 or $0.09 per diluted share for the same period in the last year. Net cash provided by operating activities was $10,227,000 against net cash used in operating activities of $3,661,000 for the same period in the last year. Purchase of property and equipment was $3,150,000 against $5,431,000 for the same period in the last year. Adjusted income from operations was $9,857,000 against $9,105,000 for the same period in the last year. Adjusted net income was $8,497,000 or $0.20 per diluted share against $7,131,000 or $0.17 per diluted share for the same period in the last year. For the six months, the company reported revenue of $112,193,000 against $107,487,000 for the same period in the last year. Income from operations was $12,956,000 against $3,489,000 the same period in the last year. Income before income taxes was $12,930,000 against $3,530,000 for the same period in the last year. Net income was $10,691,000 or $0.26 per diluted share against $1,184,000 or $0.03 per diluted share for the same period in the last year. Net cash provided by operating activities was $21,664,000 against $6,358,000 for the same period in the last year. Purchase of property and equipment was $6,255,000 against $8,222,000 for the same period in the last year. Adjusted income from operations was $22,336,000 against $18,457,000 for the same period in the last year. Adjusted net income was $18,369,000 or $0.44 per diluted share against $14,989,000 or $0.35 per diluted share for the same period in the last year. The Company reaffirmed its 2014 annual revenue guidance of between $225 and $240 million. The company currently expects its effective tax rate for the year on a GAAP basis to be below 20% and the cash tax component to be less than 50% of book tax expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $19.56 USD +0.14

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $57.71 USD -0.63
Fluidigm Corp $25.19 USD -0.275
HealthStream Inc $24.54 USD -0.04
Meridian Bioscience Inc $17.78 USD +0.03
Quidel Corp $27.02 USD +0.09
View Industry Companies
 

Industry Analysis

LMNX

Industry Average

Valuation LMNX Industry Range
Price/Earnings 49.3x
Price/Sales 3.7x
Price/Book 2.8x
Price/Cash Flow 40.3x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.